Document is current
Any future updates will be listed below
-
Authors
Lim, Kenneth J. C. https://orcid.org/0000-0002-2664-116X
Tan, Melinda
Parrondo, Ricardo https://orcid.org/0000-0002-9314-9933
Chhabra, Saurabh https://orcid.org/0000-0001-9117-8696
Dooley, Katharine
De Menezes Silva Corraes, Andre
Carabenciov, Darin
Gertz, Morie https://orcid.org/0000-0002-3853-5196
Hwa, Lisa
Haily, Stephens
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Warsame, Rahma
Cook, Joselle https://orcid.org/0000-0001-5335-9533
Binder, Moritz https://orcid.org/0000-0001-9014-9658
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Yadav, Udit
Wiedmeier-Nutor, Erin
Geyer, Susan
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
Zekeridou, Anastasia
- License Information
-
More Information
Article History
Received: 26 August 2025
Revised: 18 November 2025
Accepted: 12 December 2025
First Online: 31 December 2025
Competing interests
: K.D., A.D., D.C., L.H., H.S., P.K., M.T., T.K., R.W., J.C., M.B., U.Y., E.W., S.G.: no relevant disclosures; K.J.L.: Research funding from Sanofi; R.P.: advisory board role for Sanofi Aventis and Astra Zeneca, research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline; S.C.: honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, and research funding from Johnson & Johnson, Takeda, C4 Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca; M.G.: personal fees from Ionis/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria for Astra Zeneca, Medscape, Dava Oncology. Alexion; P.K.: Honoraria: Pharmacyclics, Sanofi, BeiGene, MustangBio, AstraZeneca, AbbVie. Consulting or Advisory Role: Sanofi. Research Funding: Amgen, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Sorrento Therapeutics, Karyopharm Therapeutics, Regeneron, Ichnos Sciences, Bristol Myers Squibb/Celgene; P.L.B.: Consultant: Oncopeptidfes. Salarius, Radmetrix, Omeros, CellCentric, AbbVie, Pfizer; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech/Rocher, Abbvie, BMS/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accommodation and expenses: Abbvie, Pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS/Celgene; S.A.: Consulting or Advisory Role: Takeda, BeiGene, GlaxoSmithKline, Sanofi, Pharmacyclics, BMS, Amgen, Janssen, Regeneron, Cellectar. Research Funding: Pharmacyclics, Janssen Biotech, Cellectar, BMS, Amgen, GlaxoSmithKline, AbbVie, Ascentage Pharma, Sanofi; R.F.: consultancy for AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific advisory board: Caris Life Sciences. Board of directors: Antengene. Patent for FISH in multiple myeloma. A.Z.: patents submitted for DACH1-IgG, PDE10A-IgG, CAMKV-IgG, Tenascin-R-IgG as biomarkers of neurological autoimmunity, received research funding from Roche/Genetech and Center for MS and Autoimmune Neurology at Mayo Clinic not relevant to this study, Consulted without personal compensation for Alexion pharmaceuticals, steering committee for the KYSA-8 study for autologous CAR-T-19 treatment for SPS; no personal compensation; Y.L.: advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, Legend, NexT Therapeutics, steering committee for Janssen, Kite/Gilead, research funding from Janssen, BMS, scientific advisory board for NexImmune, Caribou and data safety monitor board for Pfizer.
